244 related articles for article (PubMed ID: 31797075)
21. Plasminogen Activation System in Rectal Adenocarcinoma.
Razik E; Kobierzycki C; Grzegrzolka J; Podhorska-Okolow M; Drag-Zalesinska M; Zabel M; Dziegiel P
Anticancer Res; 2015 Nov; 35(11):6009-15. PubMed ID: 26504024
[TBL] [Abstract][Full Text] [Related]
22. Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease.
Qin W; Zhu W; Wagner-Mann C; Sauter ER
Ann Surg Oncol; 2003 Oct; 10(8):948-53. PubMed ID: 14527916
[TBL] [Abstract][Full Text] [Related]
23. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.
Plebani M; Herszènyi L; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F
Clin Exp Metastasis; 1997 Jul; 15(4):418-25. PubMed ID: 9219730
[TBL] [Abstract][Full Text] [Related]
24. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
25. The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma.
Zhu C; Jiang L; Xu J; Ren A; Ju F; Shu Y
Pathol Res Pract; 2020 Apr; 216(4):152885. PubMed ID: 32113794
[TBL] [Abstract][Full Text] [Related]
26. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
[TBL] [Abstract][Full Text] [Related]
27. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
[TBL] [Abstract][Full Text] [Related]
28. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
[TBL] [Abstract][Full Text] [Related]
29. Serine proteinase activation in esophageal cancer.
Tang WH; Friess H; Kekis PB; Martignoni ME; Fukuda A; Roggo A; Zimmerman A; Büchler MW
Anticancer Res; 2001; 21(4A):2249-58. PubMed ID: 11724279
[TBL] [Abstract][Full Text] [Related]
30. Association of uPA, PAT-1, and uPAR in nipple aspirate fluid (NAF) with breast cancer.
Qin W; Zhu W; Wagner-Mann C; Folk W; Sauter ER
Cancer J; 2003; 9(4):293-301. PubMed ID: 12967140
[TBL] [Abstract][Full Text] [Related]
31. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
Chambers SK; Gertz RE; Ivins CM; Kacinski BM
Cancer; 1995 Apr; 75(7):1627-33. PubMed ID: 8826920
[TBL] [Abstract][Full Text] [Related]
32. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
33. Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients.
Taubert H; Würl P; Greither T; Kappler M; Bache M; Lautenschläger C; Füssel S; Meye A; Eckert AW; Holzhausen HJ; Magdolen V; Kotzsch M
Br J Cancer; 2010 Feb; 102(4):731-7. PubMed ID: 20051950
[TBL] [Abstract][Full Text] [Related]
34. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
[TBL] [Abstract][Full Text] [Related]
35. Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer.
Al-Janabi O; Taubert H; Lohse-Fischer A; Fröhner M; Wach S; Stöhr R; Keck B; Burger M; Wieland W; Erdmann K; Wirth MP; Wullich B; Baretton G; Magdolen V; Kotzsch M; Füssel S
Biomed Res Int; 2014; 2014():972587. PubMed ID: 24877154
[TBL] [Abstract][Full Text] [Related]
36. Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis.
Lee JH; Oh MH; Park JS; Na GJ; Gil HW; Yang JO; Lee EY; Hong SY
Korean J Intern Med; 2014 Mar; 29(2):176-82. PubMed ID: 24648800
[TBL] [Abstract][Full Text] [Related]
37. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
[TBL] [Abstract][Full Text] [Related]
38. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A
J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395
[TBL] [Abstract][Full Text] [Related]
39. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
40. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
Harbeck N; Kates RE; Schmitt M
J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
